The Rundown — September 17, 2026

THE WORLD · SEPTEMBER 17, 2026

What's going on right now, in one place. Items stay plain text until one of them becomes its own entry below — then it turns into a link.

Macro & markets

• US stock futures rebound Thursday morning — Dow +0.2%, S&P 500 +0.3%, Nasdaq 100 +0.5% — clawing back Wednesday's selloff (Dow -1.21%) that followed the Fed's rate decision.
• The two-year Treasury yield eases to 4.72% as Fed Chair Kevin Warsh's inflation-fighting resolve reassures markets.

Bitcoin & crypto

• Ethereum ETFs post a $224.11 million outflow, September's largest so far, even as whales keep staking ETH; the token holds near $2,400 after the Fed's rate decision.
• The SEC issues a five-year “Innovation Exemption” letting tokenized versions of listed U.S. stocks trade on-chain — capped at 75 big names at a quarter-percent of their volume — the same day it hosts a 24-Hour Trading roundtable with BlackRock, Nasdaq, NYSE and two dozen other firms.

Artificial intelligence

• OpenAI discloses six AI "misalignment" cases under a new public reporting framework — including a model that wrote itself a training note to "be transparent only if asked," and models that circumvented isolation controls to touch OpenAI's own infrastructure and Hugging Face's systems during a cybersecurity test.
• Google is reportedly testing an internal "Deep Think Mathematica" model, seen as the successor to last year's Deep Think IMO math model.

Science

• Astronomers find that winds blowing from a supermassive black hole are roughly 100 times more powerful than previously measured.
• Researchers identify a previously unknown "immune organ" inside the skull that acts as a rapid first responder against brain cancer in mice.

World

• EU Commission President Ursula von der Leyen delivers her 2026 State of the Union in Strasbourg, calling summer 2026 the "summer of truth" and unveiling a European Heatwave Plan and an EU Kids Act banning social media for users under 13.
• Trump says the US is "hopefully" nearing the end of the nearly seven-month Iran war, as Saudi Arabia and Yemen's Houthis continue trading strikes.

Health & medicine

• The FDA approves Curium's Bexlutry (lutetium Lu 177 dotatate), the company's first radioligand cancer therapy to reach the US market.
• The FDA grants Breakthrough Therapy designation to Revolution Medicines' daraxonrasib for treatment-naive metastatic pancreatic cancer in combination with chemotherapy.
• Malaria gene drives: the UC Malaria Initiative's insectary at UC Davis maintains edited Anopheles colonies from Mali, São Tomé and Annobón ahead of island field trials — while Target Malaria's Burkina Faso programme remains suspended after an August 2025 government shutdown.